BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  BMS Celebrates A New Day in Cancer Treatment with Approval of Opdualag

  BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.

  March 19, 2022

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Novartis’ Fortuitous Discovery Could Deliver Breakthrough in Huntington’s Disease

  Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?

  March 19, 2022

   · 

  4 min read

   · 

  Heather McKenzie
• Genetown

  ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

  ImmunoGen, Inc. announced full results from the pivotal SORAYA trial evaluating the efficacy and safety of mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with Avastin®.

  March 19, 2022

   · 

  8 min read